🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  2. VAY736, ENTECAVIR , Placebo to VAY736, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  3. VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

    Kura Oncology

    NPM1-m and KMT2A-r Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  4. VIVITROL injection and VIVITROL Placebo Injection , 24 weeks

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine Dependence

    phase 3 small molecule completed

    1 trial

  5. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  6. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  7. VX-147 film-coated tablet, VX-147, Coated Placebo Tablet

    Vertex Pharmaceuticals (Australia) Pty.

    APOL1-mediated Proteinuric Kidney Disease (AMKD)

    phase 3 small molecule active

    1 trial

  8. VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, Placebo for 75 mg Rimegepant, Placebo for 50 mg rimegepant, 50 mg oral lyophilisate, Placebo for 35 mg rimegepant, Placebo for 25 mg Rimegepant, 25 mg oral lyophilisate

    Pfizer Australia Pty Ltd

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  9. VYDURA 75 mg oral lyophilisate, matching placebo for 75 mg oral lyophilisate

    Pfizer Australia Pty Ltd

    Menstrual Migraine

    phase 3 small molecule active

    1 trial

  10. Valbenazine, Valbenazine, Placebo for valbenazine capsules

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  11. Vedolizumab Placebo

    Takeda

    Hematopoietic Stem Cells

    phase 3 small molecule completed

    1 trial

  12. Veltassa 8.4 g powder for oral suspension, Placebo

    Istituto Gentili S.r.l.

    End Stage Kidney Disease on chronic dialysis therapy

    phase 3 small molecule active

    1 trial

  13. Venetoclax, Venetoclax, Cytarabine 100 mg/ml Solution for Injection or Infusion, Matching Placebo for Venetoclax, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  14. Venetoclax, Venetoclax, Matching Placebo for Venetoclax, Venetoclax, AZACITIDINE

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  15. Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use

    AbbVie Deutschland GmbH & Co. KG

    Higher-Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  16. Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet, Placebo to Match AG-120 Tablet, 250 mg, is supplied as a film-coated tablet for oral administration.

    The George Institute

    Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

    phase 3 small molecule active

    1 trial

  17. Vincristine placebo, VINCRISTINE , Polivy 140 mg powder for concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Previously Untreated Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  18. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo PH20 SC

    argenx

    Ocular Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  19. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  20. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  21. XEOMIN 200 V pulveris injekciju šķīduma pagatavošanai, Placebo to NT201, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań

    Merz Pharmaceuticals GmbH

    Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)

    phase 3 small molecule active

    1 trial

  22. XEOMIN 200 unités, poudre pour solution injectable, Placebo of Xeomin 200 U

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  23. XL092, BELZUTIFAN, XL092, XL092, Placebo to Zanzalintinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  24. XPF-010, Placebo to match XPF-010

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources